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Abstract
Resumo
Objective: To determine whether 18F-fluorodeoxyglucose positron emission tomography/computed tomography performed immedi-
ately after percutaneous ablation (iPA18F-FDG PET/CT) is useful in evaluating the outcomes of the procedure.
Materials and Methods: This was a retrospective study of 20 patients (13 males, 7 females; mean age, 65.8 ± 12.1 years) submit-
ted to percutaneous ablation of metastases. All of the lesions treated had shown focal uptake on a 18F-FDG PET/CT scan obtained 
at baseline. The primary tumors were mainly colorectal cancer (in 45%) or lung cancer (in 40%). iPA18F-FDG PET/CT was performed 
to identify any residual viable tumor cells. The treatment was considered a success (no viable tumor cells present) if no uptake of 
18F-FDG was noted on the iPA18F-FDG PET/CT scan.
Results: Twenty-six lesions were submitted to percutaneous ablation with either cryoablation (n = 7) or radiofrequency ablation (n 
= 19). The mean lesion diameter was 2.52 ± 1.49 cm. For the detection of viable tumor cells, iPA18F-FDG PET/CT had a sensitivity, 
specificity, accuracy, positive predictive value, and negative predictive value of 66.7%, 95%, 88.5%, 80%, and 90.5%, respectively. 
There was a significant correlation between the iPA18F-FDG PET/CT findings and the results of the follow-up studies (kappa = 0.66; 
p < 0.01).
Conclusion: iPA18F-FDG PET/CT studies appear to constitute a useful means of evaluating the outcomes of percutaneous ablation. 
By detecting residual viable tumor cells, this strategy might allow early re-intervention, thus reducing morbidity. Studies involving 
larger numbers of patients are needed in order to confirm our findings.
Keywords: Fluorodeoxyglucose F18; Positron-emission tomography/methods; Tomography, X-ray computed/methods; Ablation tech-
niques; Cryosurgery/methods; Radiofrequency ablation.
Objetivo: Demonstrar se a tomografia por emissão de pósitrons acoplada a tomografia computadorizada usando-se fluorodesoxi-
glicose marcada com flúor-18 realizada imediatamente após ablação percutânea (iAP18F-FDG PET/CT) pode ser útil na avaliação do 
resultado desse tratamento.
Materiais e Métodos: Foram avaliados, retrospectivamente, 20 pacientes (13 homens e 7 mulheres; média de idade: 65,8 ± 12,1 
anos) submetidos a ablação percutânea de metástases apresentando captação de 18F-FDG no exame de PET/CT. Os tumores pri-
mários foram, principalmente, câncer colorretal (45%) ou câncer de pulmão (40%). A iAP18F-FDG PET/CT foi realizada para avaliar 
tumor residual viável. O tratamento foi considerado sucesso (sem lesão viável) se nenhuma captação de 18F-FDG fosse observada 
na iAP18F-FDG PET/CT.
Resultados: Vinte e seis lesões foram submetidas a ablação percutânea por meio de crioablação (n = 7) ou radiofrequência (n = 
19). O tamanho médio das lesões era de 2,52 ± 1,49 cm. A iAP18F-FDG PET/CT detectou tumor viável com sensibilidade, especifi-
cidade, acurácia, valor preditivo positivo e valor preditivo negativo de 66,7%, 95%, 88,5%, 80% e 90,5%, respectivamente. Houve 
correlação significativa entre os achados da iAP18F-FDG PET/CT e os resultados do seguimento clínico dos pacientes (kappa = 0,66; 
p < 0,01).
Conclusão: A iAP18F-FDG PET/CT é capaz de avaliar o resultado da ablação percutânea e poderá permitir reintervenção precoce 
de lesões residuais viáveis, reduzindo a morbidade. Um número maior de pacientes é necessário para confirmar esses achados.
Unitermos: Fluordesoxiglicose F18; Tomografia por emissão de pósitrons/métodos; Tomografia computadorizada/métodos; Técni-
cas de ablação; Criocirurgia/métodos; Radiofrequência.
0100-3984 © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem
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INTRODUCTION
For cancer patients, the primary treatment with curative 
intent is surgery. However, some patients—such as those 
whose clinical condition make them poor candidates for 
surgery and those whose lesions are located at difficult-to-
access sites—are treated with percutaneous ablation. This 
approach is becoming more common in clinical practice 
because of its minimally invasive nature and low complica-
tion rates. For situations such as those cited above, a wide 
variety of percutaneous ablation techniques have been 
developed(1). For primary tumors and metastases of solid 
tumors, the use of cryoablation or radiofrequency ablation 
has increased the possibility of cancer control in patients 
who are not good surgical candidates.
Percutaneous cryoablation is a minimally invasive 
technique that consists in image-guided insertion of probes 
into the tumor and the subsequent application of succes-
sive freeze-thaw cycles, reaching temperatures as low as 
−140°C. This strategy causes tissue destruction by break-
ing cell membranes through phase change and intracellu-
lar ice crystal formation. The freezing mechanism is due 
to the thermodynamic property of argon, which undergoes 
severe heat loss during its expansion in a closed chamber 
(the Joule-Thomson effect). Thawing is achieved by replac-
ing the argon with helium, whose expansion has the op-
posite effect, heating the system. At the beginning of the 
freeze cycle, an ice ball forms at the end of the probe. The 
growth of the ice ball can be controlled by adjusting the 
probe parameters and can be accurately monitored with 
computed tomography (CT). The outermost layer of the 
ice ball, as visualized on CT or magnetic resonance imag-
ing (MRI), is less effective than is its central portion and 
must therefore be at least 0.5 cm beyond the limits of the 
target tumor. The ability to view and monitor the expansion 
of the ice ball by CT or MRI allows the treatment of the 
entire tumor to be optimized and reduces the risk of injury 
to adjacent structures. The cryogenic damage occurs not 
only at the cellular level; it also affects the microcirculation 
surrounding the target tissue. In the days that follow cryo-
ablation, the damage caused by the freezing of the tissue 
promotes platelet aggregation and ischemic injury, leading 
to tissue necrosis(2). Cryoablation has been used success-
fully to treat a variety of benign and malignant diseases in 
different locations, including the liver, kidneys, breast, and 
prostate(3–6).
Radiofrequency ablation is performed by introducing 
energy into the tissue through an active electrode, caus-
ing the ions within the tissue to vibrate under alternating 
currents. That movement of particles results in heating of 
the tissue by friction reaching temperatures above 60°C, 
causing coagulation necrosis around the electrode. The ad-
vantage of this thermal intervention is its capacity to heat 
the tissue to a lethal temperature at a specific anatomic 
location(7).
After percutaneous ablation, it is crucial to evaluate 
the treatment outcome, in order to avoid recurrence. Fol-
low-up studies with CT and MRI are not able to differenti-
ate between scar tissue and viable tumor cells, particularly 
in the lungs, and early follow-up studies typically produce 
inconclusive findings, regardless of whether the technique 
employed was cryoablation or radiofrequency ablation(8,9).
Whole-body studies with 18F-fluorodeoxyglucose posi-
tron emission tomography/computed tomography (18F-
FDG PET/CT) have been used in a variety of malignan-
cies(10–12). The technique has been used successfully to 
monitor treatment response after chemotherapy and radio-
surgery, either visually or by calculating standardized up-
take value (SUV) to quantify the response(13).
Because coagulation necrosis does not take up 18F-
FDG(14), the use of 18F-FDG PET/CT may be an efficient 
means of evaluating the outcome of percutaneous ablation. 
Viable tumor cells can be detected by 18F-FDG PET/CT 
earlier than morphological changes can be depicted by CT 
and MRI. However, 18F-FDG is not a specific tracer for 
viable tumor cells and can be taken up by inflammatory 
processes. Consequently, there can be 18F-FDG uptake in 
the tissue surrounding the treated region, due to the in-
flammation induced by percutaneous ablation. However, 
such inflammation does not develop immediately after per-
cutaneous ablation, appearing only hours later. Therefore, 
the optimal time to perform 18F-FDG PET/CT imaging 
of patients who have undergone percutaneous ablation is 
within the first few hours after the procedure(15).
The purpose of this pilot study was to determine 
whether 18F-FDG PET/CT performed immediately after 
percutaneous ablation (iPA
18F-FDG PET/CT) is an efficient 
means of evaluating the outcome of percutaneous ablation. 
To that end, we reviewed the records of a sample of pa-
tients in whom this strategy was employed.
MATERIALS AND METHODS
Patient data
This was a retrospective study of patients who were 
submitted to percutaneous ablation. The local institu-
tional review board approved this study (IRB Reference 
No. 2013-19). We included all patients with solid tumor 
metastases from various types of primary tumors in whom 
percutaneous ablation was indicated and there was focal 
uptake of 18F-FDG prior to percutaneous ablation.
The inclusion criteria were having undergone percu-
taneous ablation (cryoablation or radiofrequency ablation), 
having had a baseline 18F-FDG PET/CT scan within the 
last 30 days prior to percutaneous ablation, and the base-
line scan having shown 18F-FDG uptake in the solid me-
tastasis targeted. Patients in whom there was a change in 
the chemotherapy regimen were excluded, as were those in 
whom chemotherapy was initiated during the first 6 months 
after percutaneous ablation because of recurrence at sites 
other than the site targeted in the percutaneous ablation.
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Each patient underwent another iPA
18F-FDG PET/CT, 
the intent being to evaluate the outcome of the procedure.
The treatment was considered a success (no viable le-
sion remaining) if no 18F-FDG uptake was seen on the 
iPA
18F-FDG PET/CT images. Regardless of the iPA
18F-FDG 
PET/CT results, patients were not submitted to a new 
intervention and were followed through clinical examina-
tion and imaging modalities. The follow-up studies were 
performed with 18F-FDG PET/CT, MRI, or contrast-en-
hanced CT. If suspicious uptake was noted on the iPA
18F-
FDG PET/CT scan, the patient in question was submit-
ted to closer surveillance. Re-intervention occurred only if 
one of the follow-up studies revealed abnormalities.
Baseline 18F-FDG PET/CT studies
The baseline 18F-FDG PET/CT studies performed at 
our institution were acquired with the protocol described 
below. All of the baseline scans were performed within the 
last 30 days prior to percutaneous ablation.
Patients were required to fast for 6 h prior to the injec-
tion of 18F-FDG, in order to achieve a blood glucose level 
below 140 mg/dL. All patients received 18F-FDG at a dose 
of 7.77 MBq/kg (0.21 mCi/kg) while resting in a dark, quiet 
room.
Whole-body PET/CT scans were acquired 60 min after 
18F-FDG injection. The images were acquired on a high-
resolution imaging platform (Biograph TruePoint; Siemens 
Medical Solutions, Knoxville, TN, USA) with lutetium oxy-
orthosilicate crystal detectors, 16-slice CT detectors, and 
a spatial resolution of 4.2 mm. The image post-processing 
was performed with Syngo MultiModality Workplace soft-
ware (Siemens Medical Solutions). The PET images were 
acquired after the CT images (5 min per bed position). Im-
ages were submitted to iterative reconstruction in the axial, 
coronal, and sagittal planes, CT being used for attenua-
tion correction. The maximum SUV (SUVmax), was calcu-
lated for each lesion. Two experienced nuclear medicine 
physicians and a radiologist analyzed the images. Discor-




To perform the iPA
18F-FDG PET/CT studies, the pa-
tients were referred to the Division of Nuclear Medicine 
1–14 h after the percutaneous ablation procedure. The 
time to perform the iPA
18F-FDG PET/CT study after percu-
taneous ablation varied, depending on the condition of the 
patient after the percutaneous ablation procedure.
Patients were required to remain in a fasting state for 6 
h after percutaneous ablation (i.e., 6 h prior to the injection 
of 18F-FDG), in order to achieve a blood glucose level below 
140 mg/dL. All patients received 18F-FDG at a dose of 7.77 
MBq/kg (0.21 mCi/kg) while resting in a dark, quiet room.
Images of the lesion submitted to percutaneous abla-
tion were acquired 60 min after 18F-FDG injection. The 
images were acquired and reconstructed on the same PET/
CT equipment described above. The SUVmax was calculated 
for each lesion.
The two nuclear medicine physicians and radiologist 
who had evaluated the baseline 18F-FDG PET/CT scans 
also analyzed the iPA
18F-FDG PET/CT images, and discor-
dant findings were reviewed by a third experienced nuclear 
medicine physician. The SUV of the baseline 18F-FDG PET/
CT was not used for comparison with that of the iPA
18F-
FDG PET/CT, because some of the baseline studies were 
performed on PET/CT equipment at different institutions.
Percutaneous ablation procedures
Prior to each percutaneous ablation procedure (radio-
frequency ablation or cryoablation), the patient underwent 
a blood coagulation assessment, consisting of a complete 
blood count, as well as the determination of hemoglobin, 
hematocrit, prothrombin time, partial prothrombin time, 
and platelet count. All percutaneous ablations were per-
formed under general anesthesia with endotracheal intu-
bation.
In the operating room, the ablation probes were care-
fully placed within the tumor under ultrasound, CT, or 
MRI guidance. Prior to needle insertion, the point of entry, 
the safest trajectory, and the final position of the needle 
were carefully planned. Once the needle had been inserted, 
the point of entry was confirmed by axial images of a con-
trast-soaked cotton pledget that was placed over the lesion. 
If needed, local anesthesia was given along the needle tract 
up to the surface of the target organ. 
In cases of multiple lesions in the liver, the lesions were 
submitted to percutaneous ablation only if they were at 
least 5.0 cm apart. Lesions in the lungs were submitted to 
percutaneous ablation if they were located more than 1.0 
cm from the hilum. Whenever aerated lung tissue was tra-
versed, a thoracic surgeon would insert an intercostal drain-
age tube for the management of large pneumothoraces.
Radiofrequency ablation procedure
In the patients who underwent radiofrequency abla-
tion, we used an electrosurgical radiofrequency generator 
(1500X; RITA Medical Systems, Fremont, CA, USA). The 
generator employed provides monopolar radiofrequency 
and delivers 150 W of power in most modes with up to 200 
W of power in the infusion mode. The radiofrequency elec-
trodes consist of a deployable array of hooks, all equipped 
with thermocouples. Those are connected to a main cable 
and deliver radiofrequency energy from the generator to the 
electrode. The dispersive electrodes complete the electrical 
circuit and provide the return path for the radiofrequency 
energy applied by the device. The type of needle electrode 
used was determined by the size, location, and geometry 
of the tumor. Subsequently, the radiofrequency electrode 
was positioned along the anesthetized tract such that its tip 
was approximately 1.0 cm from the geometric center of the 
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lesion. The expandable array of electrodes was deployed 
in stages, and the tumor was progressively ablated. Tumor 
ablation was performed by applying sustained progressive 
heating. The entire tumor, together with a 1.0 cm margin 
of normal tissue, was ablated. The radiofrequency ablation 
session typically lasted 10–15 min. Treated areas had 0.5–
1.0 cm tumor-free margins.
Cryoablation procedure
The cryoablation system (Cryocare; Endocare, Irvine, 
CA, USA) included a probe with a 2.4-mm outer diameter. 
The number and size of the probes used were based on the 
size and location of the tumor, as well as on the anticipated 
geometry of the ice ball. In general, more than one probe 
was used when treating larger tumors (because of the larger 
ice ball formation) and when treating lung lesions near ves-
sels (to better overcome the heat-sink effect). Tumor abla-
tion was typically performed with overlapped sessions or 
with an ice ball margin. The intention was to ablate the 
entire tumor with a tumor-free margin of 1.0 cm.
Statistical analysis
We calculated the proportion of cases in which the per-
cutaneous ablation was successful, in order to determine 
the agreement between the iPA
18F-FDG PET/CT result and 
that of the follow-up study (performed approximately 6 
months later). The kappa coefficient was calculated. The 
mean size of the lesions submitted to cryoablation was 
compared with that of the lesions submitted to radiofre-
quency ablation using the Student’s t-test.
RESULTS
Percutaneous ablation was performed in 20 patients 
(13 of whom were male), ranging in age from 43 to 83 
years (mean age, 65.8 ± 12.1 years). A total of 26 lesions 
were submitted to percutaneous ablation: cryoablation (n 
= 7) or radiofrequency ablation (n = 19). The mean lesion 
diameter was 2.52 ± 1.49 cm. Primary tumors were mainly 
colorectal cancer (in 45%) or lung cancer (in 40%). Other 
malignancies included sarcomas, thymomas, malignant 
melanomas, and ovarian cancers. Metastatic lesions were 
located in the liver (in 50%), the lungs (in 30%), and other 
sites in the abdomen (in 19.2%), including intraperitoneal 
and retroperitoneal lymph nodes (Table 1).
The mean time from percutaneous ablation to the 
iPA
18F-FDG PET/CT scan was 6.2 ± 3.7 h (range, 1–14 h). 
As can be seen in Figure 1, the SUVmax was undetectable, 
indicating that there was no viable tumor, in 20 (76.9%) 
of the 26 scans. In the six remaining lesions, the SUVmax 
ranged from 1.8 to 5.3 (Figure 2). The time from the per-
cutaneous ablation to the follow-up study for evaluation of 
the outcome of the procedure ranged from 2 months to 11 
months (mean, 6.9 ± 4.2 months). As detailed in Table 2, 
the follow-up studies were performed with 18F-FDG PET/
CT (in 13 cases), CT (in 12 cases), or MRI (in one case).
For the detection of a viable tumor, iPA
18F-FDG PET/CT 
was found to have a sensitivity, specificity, accuracy, posi-
tive predictive value, and negative predictive value of 66.7%, 
95%, 88.5%, 80%, and 90.5%, respectively. Figure 3 shows 
side-by-side comparisons of 18F-FDG PET/CT studies con-
ducted at baseline, immediately after percutaneous ablation, 
at 3 months after the procedure, and after a second percu-
taneous ablation (14 months after the first procedure). As 
can be seen in Table 3, there was a significant correlation 
between the iPA
18F-FDG PET/CT findings and the results of 
the follow-up study (kappa = 0.66; p < 0.01).
Table 1—Characteristics of the 20 patients submitted to percutaneous abla-









































Table 2—Characteristics of the 26 lesions in the iPA18F-FDG PET/CT studies 
and in the follow-up imaging studies.
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Table 4 shows a comparison between the two percuta-
neous ablation techniques employed. The lesions submit-
ted to cryoablation were larger than were those submitted 
to radiofrequency ablation (1.47 ± 1.12 cm vs. 2.91 ± 1.43 
cm), and the difference was significant (p = 0.025).
DISCUSSION
The detection of viable tumor cells after percutaneous 
ablation has been a challenge for physicians, because the 
capillaries around the ablation site are particularly leaky in 
the weeks to months after radiofrequency ablation. That 
limits the ability of intravenous contrast-enhanced CT or 
MRI to differentiate between perilesional hemorrhage and 
residual tumor during this period(16).
Because 18F-FDG can accumulate in inflammatory 
cells, an iPA
18F-FDG PET/CT study could avoid this prob-
lem by adding information regarding the outcome of per-
cutaneous ablation. In the early post-ablation period, there 
is no inflammation to confound the findings of 18F-FDG 
PET/CT regarding viable tumor cells versus inflammatory 
cell infiltration.
There have been few studies of the performance of 
iPA
18F-FDG PET/CT in the evaluation of ablative proce-
dures, and the majority of such studies have addressed 
radiofrequency ablation. However, these studies have con-
sistently suggested that adding 18F-FDG PET and PET/CT 
to the diagnostic protocol of patients submitted to percuta-
neous ablation will provide vital information regarding the 
outcome of the procedure(17,18).
A pilot study involving eight patients submitted to ra-
diofrequency ablation suggested the possibility of using early 
18F-FDG PET/CT to avoid the influence of inflammatory ac-
tivity(19), the time from the procedure to the PET/CT scan 
ranging from 2 h to 41 h. In that study, the results were 
categorized as true negative in four of the cases, true posi-




Figure 1. A: Baseline 18F-FDG PET/CT images of a lung metastasis, performed prior to cryoablation, showing marked focal uptake within the lung lesion (arrows). B: 
iPA
18F-FDG PET/CT scan acquired at 3 h after cryoablation, showing no 18F-FDG uptake within the lesion and a rim of uptake consistent with postoperative inflammation 
(arrows). C: Follow-up 18F-FDG PET/CT images and clinical examination performed at 6 months after the procedure, showing no signs of viable tumor cells (arrows).
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A
B
Figure 2. A: Baseline 18F-FDG PET/CT images of a liver metastasis demonstrating focal uptake. B: iPA18F-FDG PET/CT images, acquired at 5 h after radio-
frequency ablation, showing no 18F-FDG uptake. Follow-up 18F-FDG PET/CT study, conducted at 6 months after the procedure, showing no signs of viable 
tumor cells.
Figure 3. A: Baseline 18F-FDG PET/CT image of a 
liver metastasis showing focal uptake (arrow). B: 
iPA
18F-FDG PET/CT image, acquired at 4 h after ra-
diofrequency ablation, showing a large region with 
no 18F-FDG uptake (curved arrow) and a small fo-
cal region with minimal residual uptake (dashed 
arrow). C: 18F-FDG PET/CT image, acquired 3 
months after radiofrequency ablation, showing 
that the small focal region with minimal residual 
uptake had increased in size and metabolism, 
consistent with the presence of residual tumor 
cells (arrow). D: The patient was submitted to an-
other radiofrequency ablation session. E: Image 
acquired at 14 months after the first procedure 
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In another study of 20 patients undergoing radiofrequency 
ablation of colorectal liver metastases(20), the time from the 
procedure to the PET/CT scan was reduced to 24 h. In that 
study, the false-positive rate was only 5% and the authors 
reported inflammation, appearing as a rim-shaped area of 
uptake around the lesion, in one case.
The time interval between the percutaneous ablation 
procedure and the 18F-FDG PET/CT study was signifi-
cantly shorter in our study than in the studies cited above. 
We decided to reduce the time between the percutaneous 
ablation procedure and the 18F-FDG PET/CT study to try 
to reduce the number of false-positive cases. Even so, we 
obtained a false-positive result in two cases (7.6%). Those 
false-positive cases both occurred in the same patient, who 
had lung metastases from colorectal cancer and underwent 
cryoablation for both lesions. The lesions sizes were 1.7 cm 
and 0.7 cm, the SUVmax being 2.1 and 1.8, respectively. In 
that patient, the iPA
18F-FDG PET/CT study was performed 
at a maximum of 14 h after the procedure. Although a mild 
diffuse rim of activity was noted around each lesion, the 
absence of uptake within the nodules was not clearly noted, 
possibly due to the small lesion sizes. Therefore, despite 
the knowledge of the possible effect of inflammation sur-
rounding the tissue, we could not conclude whether or not 
there was viable tumor within those specific lesions (Figure 
4). Follow-up CT scans obtained at 11.5 months after cryo-
ablation showed reductions in the size of those two lesions.
In cryoablation procedures, the diffuse uptake that oc-
curs around the lesion can be so intense that it makes it 
difficult to differentiate between viable and nonviable tu-
mor cells. Among the patients undergoing cryoablation of 
lung lesions in the present study, the true-negative cases 
were noted when the iPA
18F-FDG PET/CT study was per-
formed 1–4 h after the procedure. In our sample, the in-
flammatory reaction was more intense and appeared earlier 
after cryoablation of lung lesions than after radiofrequency 
ablation of liver lesions. There are no data in the literature 
that would explain these findings. Diffuse mild uptake in 
the tissue surrounding the lesion submitted to cryoablation 
should not be interpreted as residual disease. However, 
if the lesion is small, it is possible that there are residual 
viable tumor cells within the lesion. However, in the iPA
18F-
FDG PET/CT study, any focal uptake after cryoablation or 
radiofrequency ablation should be considered indicative of 
viable tumor cells.
In our study, true-negative results were obtained in 
18 (69.2%) of the 26 lesions submitted to percutaneous 
Table 3—Comparison between the results of the iPA18F-FDG PET/CT studies and 
















* Significant correlation between the iPA18F-FDG PET/CT findings and the re-
sults of the follow-up study (kappa = 0.66; p < 0.01).































* The mean lesion size prior to cryoablation and radiofrequency ablation was 
1.47 ± 1.12 cm and 2.91 ± 1.43 cm, respectively (p = 0.025, Student’s t-test).
Figure 4. A: Baseline 18F-FDG PET/CT image of a lung metastasis from colorectal cancer. Cryoablation was performed. B: iPA18F-FDG PET/CT scan, acquired at 
14 h after cryoablation, showing a rim of diffuse 18F-FDG uptake around the lesion with no clear uptake within the lesion itself. Despite the knowledge of the 
possible effect of inflammation of the surrounding tissue, it was not possible to conclude whether or not there were viable tumor cells present.
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ablation, and true-positive results were obtained in five 
(19.2%). In the five true-positive cases, there were focal 
areas of increased metabolic activity in the iPA
18F-FDG 
PET/CT study. In the follow-up studies, all of those focal 
areas increased in size or in metabolic activity, demonstrated 
residual disease. We obtained a false-negative result in one 
case (3.8%). That patient had undergone cryoablation of 
a 3.0-cm lung metastasis from malignant melanoma. To 
completely destroy a tumor, the area of ablation must ex-
ceed the tumor periphery. Because the lesion submitted 
to cryoablation in that case was large, some tumor cells 
may have remained in the tumor periphery and the num-
ber of viable tumor cells was not enough to be detected in 
the iPA
18F-FDG PET/CT. The follow-up was performed 2 
months later and detected tumor recurrence, which was 
to be expected, given that colorectal cancer cells are highly 
aggressive and fast growing(21).
In the present study, the sensitivity of iPA
18F-FDG PET/
CT was only 66.7%, which might be due to the inability of 
the method to detect very small lesions. Unfortunately, this 
difficulty occurs with all of the imaging modalities currently 
available. There is a minimal quantity of cells necessary to 
be detected by the 18F-FDG tracer.
Despite its low sensitivity, the iPA
18F-FDG PET/CT 
study showed high specificity, accuracy, and negative pre-
dictive value (95%, 88.5%, and 90.5%, respectively). These 
findings suggest that a positive iPA
18F-FDG PET/CT result 
likely represents residual viable tumor cells and indicates 
that re-intervention should be considered. There was a sig-
nificant correlation between the iPA
18F-FDG PET/CT find-
ings and the follow-up results. Knowledge of the efficacy 
of treatment is crucial because patients with incomplete 
ablative therapy or early recurrence may be considered 
for a repeat ablative treatment. In a study involving eight 
patients with non-small cell lung cancer submitted to ra-
diofrequency ablation followed by surgery(8), only three pa-
tients (37.5%) had no residual disease. In the remaining 
five patients, over 20% of the treated regions still had viable 
tumor cells. In another series describing 54 lung tumors(9), 
only 32 patients (59%) had complete necrosis. These re-
sults clearly indicate the need for noninvasive imaging 
techniques that allow proper, early evaluation of percuta-
neous ablation outcomes. 
Our study has some limitations. The retrospective 
design of the study introduces the possibility of certain 
biases. In addition, the fact that we evaluated the abla-
tion of metastases from a wide variety of tumors could 
have made it difficult to detect residual disease, despite 
the fact that all of the lesions showed high focal 18F-FDG 
uptake prior to percutaneous ablation.
The main strength of our study is that iPA
18F-FDG PET/
CT was shown to be feasible and that it was performed only 
a few hours after the procedure, significantly reducing the 
number of false-positive cases. In the majority of studies of 
this nature, 18F-FDG PET/CT imaging studies have been 
conducted days to weeks after percutaneous ablation, which 
reduces their specificity for viable tumor cell detection(22–24). 
We took this novel approach to evaluate the usefulness of 
this technique early after percutaneous ablation, when the 
inflammatory process has not yet begun.
CONCLUSION
The use of iPA
18F-FDG PET/CT within the first 14 h af-
ter percutaneous ablation—cryoablation or radiofrequency 
ablation—appears to be a reliable means of evaluating the 
outcome of the procedure. By detecting residual viable tu-
mor cells, this strategy might allow early re-intervention, 
thus reducing morbidity. Further studies, involving larger 
numbers of patients, are needed in order to confirm our 
findings. 
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